Apica Cardiovascular Ltd., a Galway, Ireland-based developer of an innovative transapical access and closure system, has received a €3.75m financing.
Investors include Seroba Kernel Life Sciences and Triventures.
In conjunction with the funding, Dr. Daniel O’Mahony, Partner at Seroba Kernel Life Sciences, will join the company’s board.
Apica is developing an innovative transapical access and closure system that is designed to simplify and standardize the technique used to open and close the apex of a beating heart, in order to deliver large therapeutic devices into the inner chambers of the heart in a minimally invasive manner.
The company’s technology and early prototypes were initially developed at the Georgia Institute of Technology and Emory University, Atlanta, USA by a founding team with extensive cardiovascular, engineering, and regulatory experience.
Initial seed funding was provided by the Coulter Foundation Translational Research Program and Georgia Research Alliance “Venture Lab” Program.
Led by CEO, James L. Greene, the company is now moving to Ireland and will be based at the Innovation Centre in NUI Galway.